Fig. 6From: The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphomaThe application of small molecules agents in R/R DLBCLs. Several biomarkers are potentially targeted in R/R DLBCLs, including BCR (PI3K, MTOR), BCL2, XPO1, NF-κB, and CARD11-BCL10-MALT1 inhibitorsBack to article page